The preimplantation genetic testing market is estimated to grow at a CAGR of 10.70% during the forecast period. It was valued at US$808.519 million in 2022 and is projected to reach US$1,647.489 million by 2029.
Preimplantation genetic diagnosis (PGD) is implemented before the IVF procedure. Women who have had many miscarriages and final pregnancies with chromosome abnormalities have PGD sent in IVF cycles.
Couples who are at chance of genetic disorders can asset from preimplantation genetic testing. The major variable impacting the preimplantation genetic treatment industry’s expansion is the developing frequency of infertility among people and rising hereditary issues.
Furthermore, preimplantation genetic testing is increasing in demand because it detects imperfect embryos and has some genetic disorders and other deficiencies that lead to the child being born with health abnormalities. People who have single-quality benefactors, sex-linked genetic disorders, chromosomal issues, or a history of numerous abortions are progressively utilizing preimplantation genetic testing strategies.
Many genetic deformities cause newborn deaths worldwide and hence will propel the preimplantation genetic treatment market growth. For instance, according to UNICEF, in 2022, the global mortality rate for neonatal deaths was estimated at 11 deaths per 1,000 children after the first month and before reaching age 1 and 9 deaths per 1,000 children after reaching age 1 and before age 5, resulting in approximately 6,300 neonatal deaths daily. Preimplantation genetic diagnosis helps in curbing this issue as it detects defective chromosomes at an early stage and prevents congenital genetic deformities in the fetuses. As the women’s age for childbearing increases, so does the use of preimplantation genetic testing.
The polymerase chain reaction (PCR) is expected to hold the greatest share amid the estimated period owing to the major market penetration and rising cost-effectiveness with high accuracy of these tests are fueling the preimplantation genetic treatment industry. The PCR response raises the chance of detection of any chromosomal variations from the norm with a huge number of copies of a specific extent of the genome. This technological innovation is appropriate for the detection of all types of hereditary or genetic disorders.
The major variable driving the preimplantation genetic treatment market expansion is the increasing awareness among healthcare experts and customers about the genetic testing industry. The rising incidence of single gene disease and translocation cases led to the effective delivery of NGS technology for genetic testing. The preimplantation genetic diagnosis services help reduce the incidences of genetic diseases, which is done by embryo examination to determine specific gene mutations. The PGS services are also gaining popularity as they are suggested for couples with multiple IVF cycles, advanced age, and recurrent pregnancy loss.
A study presented at the National Society of Genetic Counselors' 41st Annual Conference in November 2022 reveals a significant increase in preimplantation genetic testing (PGT-M) as part of in vitro fertilization (IVF). The study found that the use of PGT-M increased by over 644% over a 17-year period, from 1% in 2004 to 7.44% of all IVF cycles in 2021, likely due to the rise in carrier screening and other genetic testing methods.
Besides, preimplantation genetic testing plays an imperative role in IVF prognosis because it is fundamental to examine the medical condition of the embryos, subsequently contributing to the development of IVF prognosis. The rise in demand for in vitro fertilization methods is increasing the request for preimplantation genetic testing methods. Additionally, many product launches by major market players are further fueling the preimplantation genetic treatment market growth. Rising infertility and increasing preference for IVF procedures are expected to drive the preimplantation genetic treatment market growth during the forecast period.
The growing demand for improved medical services and increasing income fuel opportunities for developing advanced diagnostic and treatment approaches. As the need to prevent physical abnormalities and health problems has increased, the preimplantation genetic treatment market has grown for early diagnostic approaches. These early diagnostic approaches are used during genetic invitro fertilization and other artificial insemination procedures. Preimplantation genetic testing strategies can detect inherited disorders, including inherent hearing loss, cystic fibrosis, and numerous more.
Next-generation sequencing (NGS) drives the preimplantation genetic treatment industry due to its accuracy, productivity, and comprehensive genetic data. The NGS strategy gives detailed hereditary examination, which results in progressed success rates of assisted reproductive methods. Besides, the adoption of florescent in-situ hybridization is additionally affecting the preimplantation genetic treatment industry due to the increasing need to detect chromosomal variations from the norm in embryos before implantation. Fish offers quick results and screens a constrained number of chromosomes at a time.
The European region is anticipated to secure a sizable preimplantation genetic treatment market share. The industry will be fueled by the increasing prevalence of late pregnancies, the growing liberal screening regulations in various European countries, and the presence of leading market players.
Furthermore, Asia Pacific is anticipated to grow significantly during the forecast period due to advancements in reproductive health. High adoption of IVF and increasing consumer awareness are further fueling the preimplantation genetic treatment market growth.
| Report Metric | Details |
|---|---|
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |